细胞疗法开发商FibroBiologics宣布完成与首席科学官达成的50万美元私募配售-动脉网

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

CISION 等信源发布 2026-09-17 20:30



可切换为仅中文







HOUSTON

休斯顿

，

Sept. 17, 2026

2026年9月17日

/PRNewswire/ -- FibroBiologics, Inc. (Nasdaq:

/PRNewswire/ -- FibroBiologics, Inc.（纳斯达克：

FBLG

) ('FibroBiologics' or the 'Company'), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of a private placement on September 15, 2026, with Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, for the purchase of 298,508 shares of common stock and accompanying warrants to purchase up to 298,508 shares of common stock, priced at-the-market under Nasdaq rules..

FibroBiologics（简称“FibroBiologics”或“公司”）是一家处于临床阶段的生物技术公司，拥有270多项已授予和待批的专利，专注于利用成纤维细胞及成纤维细胞衍生材料开发慢性疾病的治疗药物和潜在治愈方案。该公司今日宣布，已于2026年9月15日完成与FibroBiologics首席科学官Hamid Khoja博士的私募配售交割。根据纳斯达克规则下的市价定价，Khoja博士购买了298,508股普通股，以及随附的认股权证，该权证允许其最多再购买298,508股普通股。

Each share of common stock and accompanying warrant was sold at a combined purchase price of $1.675. This price equaled the consolidated closing bid price of the Company's common stock on The Nasdaq Capital Market on September 14, 2026, of $1.55 per share, plus $0.125 per warrant. The warrants have an exercise price of $1.55 per share, are immediately exercisable, and expire five years from the date of issuance..

每股普通股及随附的认股权证以合计1.675美元的购买价格出售。该价格等于2026年9月14日公司在纳斯达克资本市场普通股的合并收盘价每股1.55美元，加上每份认股权证0.125美元。认股权证的行权价格为每股1.55美元，可立即行权，并自发行之日起五年后到期。

FibroBiologics received gross proceeds of approximately $0.5 million, before deducting offering expenses. The Company intends to use the net proceeds for general corporate purposes and working capital.

FibroBiologics在扣除发行费用前获得了约50万美元的总收益。公司打算将净收益用于一般企业用途和营运资金。

'Dr. Khoja is the scientific architect of our platform, and his decision to increase his investment as a shareholder speaks for itself,' said Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics. 'With CYWC628 advancing in the clinic and our pipeline expanding across wound care, psoriasis and orthopedics, we are focused on execution, and this investment reflects the confidence our leadership team has in the work ahead.'.

“Khoja 博士是我们平台的科学架构师，他作为股东决定增加投资，这一举动本身便足以说明一切，”FibroBiologics 创始人兼首席执行官 Pete O'Heeron 表示。“随着 CYWC628 在临床试验中取得进展，以及我们的产品线在伤口护理、银屑病和骨科领域不断拓展，我们正专注于执行落地，而此次投资反映了我们的领导团队对未来工作的信心。”

'I have spent years working with our passionate and dedicated team to build our fibroblast-based platform technology, and our discoveries every day continue to reinforce my confidence in the potential therapeutic capabilities of these cells,' said Dr. Khoja. 'Investing in FibroBiologics is my personal commitment to the science we are building, the team we have built, and the potential of the therapeutics we are developing for the patients we hope to serve.'.

“多年来，我与充满热情且敬业的团队共同努力，构建了基于成纤维细胞的平台技术。我们每天的发现都不断坚定我对这些细胞潜在治疗能力的信心。”Khoja博士表示。“投资FibroBiologics是我个人对我们所构建的科学、我们所打造的团队以及我们正在为患者开发的疗法潜力的承诺。”

The securities described above were offered and sold in a private placement pursuant to the exemption provided in Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act'), and Rule 506(b) of Regulation D promulgated thereunder. They have not been registered under the Securities Act or applicable state securities laws.

上述证券依据经修订的《1933年证券法》（以下简称“《证券法》”）第4(a)(2)条规定的豁免以及据此颁布的D条例第506(b)条，以私募方式发行和销售。这些证券未根据《证券法》或适用的州证券法进行注册。

Accordingly, these securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws..

因此，除非依据生效的注册声明或适用《证券法》及适用的州证券法律中关于注册要求的豁免规定，否则不得在美国境内要约或出售这些证券。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售要约或征求购买这些证券的要约，也不得在任何州或其他司法管辖区进行这些证券的销售，如果在该等州或其他司法管辖区，在根据当地证券法进行注册或资格认定之前，此类要约、征求或销售将是非法的。

For more information, please visit FibroBiologics'

更多信息，请访问 FibroBiologics

website

网站

, email FibroBiologics at

，请通过电子邮件联系 FibroBiologics，邮箱地址为

[email protected]

or follow FibroBiologics on

或在以下平台关注 FibroBiologics

领英

，

YouTube

，

Facebook

脸书

或者

。

About FibroBiologics

关于 FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer.

FibroBiologics 总部位于休斯顿，是一家处于临床阶段的生物技术公司，致力于开发一系列疗法，并利用成纤维细胞及成纤维细胞衍生材料寻求慢性疾病的潜在治愈方案。FibroBiologics 在美国及国际范围内拥有 270 多项已授予或 pending 的专利，涵盖多种临床路径，包括伤口愈合、多发性硬化症、椎间盘退变、银屑病、骨科、人类长寿以及癌症等领域。

FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit .

FibroBiologics 代表了细胞疗法和组织再生领域下一代医疗进步。欲了解更多信息，请访问。

www.FibroBiologics.com

。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性陈述的警示性声明

This communication contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the Company's intended use of proceeds. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events.

本通讯包含1995年《私人证券诉讼改革法案》所定义的“前瞻性陈述”。前瞻性陈述包括有关公司募集资金预期用途的信息。这些前瞻性陈述基于FibroBiologics管理层当前的预期、估计、预测和信念，以及有关未来事件的若干假设。

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption 'Risk Factors' and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings.

这些前瞻性陈述并非对未来业绩、状况或结果的保证，并涉及许多已知和未知的风险、不确定性、假设及其他重要因素，其中许多因素不在 FibroBiologics 管理层的控制范围内，可能导致实际结果与前瞻性陈述中讨论的结果存在重大差异，包括在 FibroBiologics 向美国证券交易委员会（SEC）提交或提供的年度报告、季度报告和当前报告（即 10-K 表格、10-Q 表格和 8-K 表格）以及任何后续公开文件中“风险因素”标题下及其他部分所列明的因素。

Copies are available on the SEC's website, .

副本可在美国证券交易委员会（SEC）网站上获取。

www.sec.gov

. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics' R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications.

这些风险、不确定性、假设及其他重要因素包括但不限于：(a) 与 FibroBiologics 的流动性及其维持开展业务所需充足资本资源的能力相关的风险；(b) 对 FibroBiologics 研发工作及临床前研究的启动、进展和预期结果的期望；(c) 研发及临床前研究结果与临床研究结果之间不可预测的关系；以及 (d) FibroBiologics 成功推进其专利申请的能力。

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

前瞻性陈述仅在其作出之日有效。提醒读者不要过度依赖前瞻性陈述，FibroBiologics 不承担任何义务，且除法律要求外，不打算因新信息、未来事件或其他原因更新或修订这些前瞻性陈述。

FibroBiologics gives no assurance that it will achieve its expectations..

FibroBiologics 不保证其能够实现预期目标。

General Inquiries:

一般咨询：

[email protected]

Investor Relations:

投资者关系：

Nic Johnson

尼克·约翰逊

Russo Partners

鲁索合伙人